Topical fibronectin treatment in persistent corneal epithelial defects and corneal ulcers.
Topical fibronectin, autologous and homologous, was used to treat nine patients (eleven eyes) with persistent corneal epithelial defects and corneal ulcers that failed to improve with standard therapy. The fibronectin was purified from autologous and homologous plasma by gelatin-Sepharose 4B affinity chromatography and administered topically, 500 micrograms/ml five times a day, for three weeks. Complete or nearly complete reepithelialization was achieved in all patients regardless of the source of fibronectin, autologous or homologous. But healing times varied. The average healing time was 41.7 +/- 14.7 days (35.7 +/- 12.4 days for autologous, 50.8 +/- 14.4 days for homologous). Ocular symptoms were relieved significantly, and no side effects were observed. Over an average follow-up period of 5.2 months, no recurrences were noted. The results showed that homologous, as well as autologous, fibronectin was effective in patients with persistent corneal epithelial defects and corneal ulcers.
Kim
K S
KS
Department of Ophthalmology, School of Medicine, Keimyung University, Tokyo, Korea.
Oh
J S
JS
Kim
I S
IS
Jo
J S
JS
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D001798:Blood Proteins / Q000302:isolation & purification; D002846:Chromatography, Affinity; D003316:Corneal Diseases / Q000188:drug therapy*; D003320:Corneal Ulcer / Q000188:drug therapy*; D004848:Epithelium / Q000187:drug effects; D005260:Female; D005353:Fibronectins / Q000008:administration & dosage / Q000302:isolation & purification / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D014792:Visual Acuity; D014945:Wound Healing / Q000187:drug effects
D001798:Blood Proteins; D005353:Fibronectins